CEO Total Pay
$6.3M
FY2024 Summary Compensation, below median
KROS FY2024 SEC EDGAR DEF 14A
Keros Therapeutics, Inc. CEO pay ratio
The CEO earned $6.3M in FY2024 against median worker pay of $376,639 · Chemicals & Pharmaceuticals.
- State
- MA
- Filing date
- 2025-04-23
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2024
Data updated August 2026
Subscribe to Keros Therapeutics, Inc. CEO pay filing updates (RSS)
CEO-to-worker pay ratio
17:1
Below Average (Scale: 0–1000:1)
CEO pay
$6.3M
Median worker
$376,639
Latest filing FY2024. This company's newest DEF 14A on file is for FY2024, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Keros Therapeutics, Inc. reported a 17:1 CEO-to-worker pay ratio in FY2024 - at or below the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 17:1
- FY2024 disclosed
- CEO total
- $6.3M
- Summary Compensation Table total
- Median worker
- $376,639
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2024
A component-level pay breakdown is not reported in Keros Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
17:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$6.3M
Companies in Industry
168
vs. Industry Median
Below
Keros Therapeutics, Inc.: near-parity Item 402(u) ratio
Keros Therapeutics, Inc. stamps FLOOR · ELITE-MED at 17:1 against $376,639 median worker pay in FY2024. the CEO earned 17× the median employee ($376,639) in FY2024.
At $376,639 median worker pay, the FLOOR stamp is near pay-parity territory under HEAVY CEO total.
Pay Ratio
17:1
Below typical
What FY2024 shows for Keros Therapeutics, Inc.
Keros Therapeutics, Inc. stamps FLOOR · ELITE-MED at 17:1 against $376,639 median worker pay in FY2024. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Keros Therapeutics, Inc.'s $6.3M CEO total is at or below the $7.9M industry median CEO pay.
Keros Therapeutics, Inc. stamps FLOOR · HEAVY · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2024
- Total Compensation
- $6.3M
- Median Employee Pay
- $376,639
- Pay Ratio
- 17:1
- Filing Date
- 2025-04-23
Company Info
- Ticker
- KROS
- CIK
- 1664710
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2834
- State
- MA
SEC EDGAR DEF 14A for CIK 1664710, FY2024. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Keros Therapeutics, Inc. stamps FLOOR · ELITE-MED at 17:1 against $376,639 median worker pay in FY2024.
Read with Keros Therapeutics, Inc.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · HEAVY · ELITE-MED.
Enviri LLC · HEAVY
ABS(ceo_total_comp) peer at $6.3M (Δ $7K lighter vs Keros Therapeutics, Inc.); MID · PAR-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Essential Utilities, Inc. · HEAVY
ABS(ceo_total_comp) peer at $6.3M (Δ $11K lighter vs Keros Therapeutics, Inc.); MODEST · HIGH-MED vs this page's FLOOR · HEAVY · ELITE-MED.
ZoomInfo Technologies Inc. · HEAVY
ABS(ceo_total_comp) peer at $6.3M (Δ $19K lighter vs Keros Therapeutics, Inc.); MODEST · ELITE-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Solaredge Technologies, Inc. · HEAVY
ABS(ceo_total_comp) peer at $6.2M (Δ $23K lighter vs Keros Therapeutics, Inc.); MID · HIGH-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Keros Therapeutics, Inc. stamps FLOOR · HEAVY · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · FLOOR
See where FLOOR · HEAVY packages sit on the national leaderboard after reading Keros Therapeutics, Inc..
Ratio primer · FLOOR
Keros Therapeutics, Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Keros Therapeutics, Inc. (CIK 1664710), FY2024. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.